Department of Biochemistry and Tissue Biology, University of Campinas, São Paulo, Brazil.
Department of Biochemistry and Tissue Biology, University of Campinas, São Paulo, Brazil.
Best Pract Res Clin Gastroenterol. 2017 Dec;31(6):643-648. doi: 10.1016/j.bpg.2017.09.011. Epub 2017 Sep 18.
Faecalibacterium prausnitzii, anaerobic bacteria, is one of the main components of gut microbiota and the most important butyrate-producing bacteria in the human colon. So far, this commensal bacterium has been considered as a bioindicator of human health, once when its population is altered (decreased), inflammatory processes are favored. Several reports in the literature highlighted that the amount of Faecalibacterium prausnitzii negatively correlates to the activity of inflammatory bowel disease and colorectal cancer. Therefore, counterbalancing dysbiosis using Faecalibacterium prausnitzii as a potential active component of probiotic formulations appears to be a promising therapeutic strategy for inflammatory bowel diseases and colorectal cancer. However, once this microbial is very sensitive to oxygen, the formulation development is a great challenge. In this review, we will focus our attention on Faecalibacterium prausnitzii biology, anti-inflammatory metabolites, modulators of this bacterium population and its impact on human health.
普拉梭菌，厌氧菌，是肠道微生物群的主要组成部分之一，也是人类结肠中最重要的产生丁酸盐的细菌。到目前为止，这种共生菌一直被认为是人类健康的生物标志物，一旦其种群发生改变（减少），炎症过程就会受到影响。文献中的几项报告强调，普拉梭菌的数量与炎症性肠病和结直肠癌的活性呈负相关。因此，使用普拉梭菌作为益生菌制剂的潜在活性成分来平衡肠道菌群失调似乎是治疗炎症性肠病和结直肠癌的一种很有前途的治疗策略。然而，由于这种微生物对氧气非常敏感，因此制剂的开发是一个巨大的挑战。在这篇综述中，我们将重点关注普拉梭菌的生物学特性、抗炎代谢产物、该细菌种群的调节剂及其对人类健康的影响。
